14.07.2008 17:00:00
|
Dr. Alan Fletcher Joins PerkinElmer as Vice President of Bio-Discovery Business Development
PerkinElmer, Inc. (NYSE: PKI),
a leader in Health Sciences and Photonics, today announced that Alan
Fletcher, Ph.D., has joined the Company as vice president, business
development for PerkinElmer’s Life and
Analytical Sciences business. In this role, Fletcher will be responsible
for growing the Bio-discovery business through the development of
strategic partnerships and alliances in the life science research area,
and the introduction of new technologies for GPCR, kinase and biomarker
drug target classes.
Fletcher brings nearly 20 years of operational, technical and commercial
experience in the drug discovery and life science industries to his new
position. "Alan’s
arrival is an important next step in the growth of our Bio-discovery
business,” said Richard Eglen, Ph.D.,
president, Bio-discovery, PerkinElmer. "He
brings both strong expertise in technology and drug discovery, as well
as proven leadership qualities that will be instrumental in further
positioning PerkinElmer as the industry’s
leading provider of cellular screening and drug discovery reagent
technologies and services.” "I am very happy to be joining PerkinElmer and
am looking forward to contributing to the Company’s
long-term success in drug discovery and research,”
said Fletcher.
Fletcher joins PerkinElmer from GE Healthcare where he held multiple
positions in the company’s life science and
discovery systems business units. Prior to this, Fletcher held a range
of leadership roles within consumer products, biotechnology, R&D, and
technology transfer for a number of Fortune 500 corporations, where he
gained extensive experience in business development, commercialization
of biological and chemical research, strategy development, and
technology assessment and development.
Fletcher has a doctorate in biochemical pharmacology from the University
of London in the United Kingdom. He has been published widely in the
areas of drug discovery and high throughput screening, and has served as
a member of the board of directors for the Society of Biomolecular
Sciences (SBS) since 2002 and as chairman of the board in 2005.
PerkinElmer’s Bio-discovery business provides
the most comprehensive offering of enabling technologies and services
including biochemistry, detection systems, cell imaging, and liquid
handling to accelerate life sciences research, from drug discovery to
academic research.
PerkinElmer, Inc. is a global technology leader driving growth and
innovation in Health Sciences and Photonics markets to improve the
quality of life. The Company reported revenues of $1.8 billion in 2007,
has 9,100 employees serving customers in more than 150 countries, and is
a component of the S&P 500 Index. Additional information is
available through www.perkinelmer.com
or 1-877-PKI-NYSE.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu PerkinElmer Inc.mehr Nachrichten
Analysen zu PerkinElmer Inc.mehr Analysen
Aktien in diesem Artikel
PerkinElmer Inc. | 109,65 | -0,77% |
Indizes in diesem Artikel
S&P 500 | 6 039,33 | -0,20% |